Details
Category: Volume 07 Issue 06 June 2019
Hits: 1017

Title: To Study the Effect of Age, Total Cholesterol and High Density Lipoproteins in Psoriasis Subjects

Authors: Dr Prabhakar Singh Bais, Dr Amitabh Agarwal, Dr Priyanka Chauhan

 DOI: https://dx.doi.org/10.18535/jmscr/v7i6.186

Abstract

Lately research report reveals that the leading cause of death for people with psoriatic arthritis is cardiovascular disease. Although higher cholesterol and lower High Density Lipoprotein (HDL) levels in psoriasis patients have been found in several studies, but, there are no reported data for psoriasis patients living in Bundelkhand region. Therefore, to assess the mean values of age, total cholesterol, and HDL in patients with psoriasis and also to compare these levels with that of healthy controls (Non-Psoriatic). Age & sex matched fifty human non-psoriatic individuals were taken into healthy control group. Fifty psoriasis subjects, on treatment were included in Psoriasis group. Age, serum cholesterol, and HDL levels were estimated according to the instructions given in the methods. Pertaining to psoriasis group subjects, a positive correlation between age with total serum cholesterol was established. In the control group also we observed a positive correlation between Age with total serum cholesterol was established. The authors conclude from the study that alterations in the cholesterol and HDL in psoriasis subjects due to deficient scavenging action of HDL. Therefore, psoriatic patients with psoriasis should be evaluated for hyperlipidemia and obstructive vascular diseases because any compensation mechanism may become insufficient.

References

  1. Global Report on Psoriasis. World Health Organization (2016) http://apps.who.int/iris/bitstream/handle/10665/204417/9789241565189_eng.pdf;jsessionid=591010E64CA363E21A372F302922AFF7?sequence=1
  2. Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA dermatology. 2015 Jun 1;151(6):651-8.
  3. Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, Stern RS, Feldman SR, Rolstad T. Epidemiology of psoriatic arthritis in the population of the United States. Journal of the American Academy of Dermatology. 2005 Oct 1;53(4):573-e1.
  4. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. Journal of the American Academy of Dermatology. 2004 Nov 1;51(5):704-8.
  5. Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, Rolstad T, Margolis DJ. The prevalence of psoriasis in African Americans: results from a population-based study. Journal of the American Academy of Dermatology. 2005 Jan 1;52(1):23-6.
  6. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. InJournal of Investigative Dermatology Symposium Proceedings 2004 Mar 1 (Vol. 9, No. 2, pp. 136-139). Elsevier.
  7. Kumar S, Nayak CS, Padhi T, Rao G, Rao A, Sharma VK, Srinivas CR. Epidemiological pattern of psoriasis, vitiligo and atopic dermatitis in India: Hospital-based point prevalence. Indian dermatology online journal. 2014 Nov;5(Suppl 1):S6.
  8. Armstrong AW, Guérin A, Sundaram M, Wu EQ, Faust ES, Ionescu-Ittu R, Mulani P. Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. Journal of the American Academy of Dermatology. 2015 Jun 1;72(6):968-77.
  9. Rehal B, Modjtahedi BS, Morse LS, Schwab IR, Maibach HI. Ocular psoriasis. Journal of the American Academy of Dermatology. 2011 Dec 1;65(6):1202-12.
  10. Zeichner JA, Lebwohl M. Potential complications associated with the use of biologic agents for psoriasis. Dermatologic clinics. 2007 Apr 1;25(2):207-13.
  11. Noe MH, Shin DB, Wan MT, Gelfand JM. Objective Measures of Psoriasis Severity Predict Mortality: A Prospective Population-Based Cohort Study. The Journal of investigative dermatology. 2018 Jan;138(1):228-30.
  12. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, Margolis DJ, Strom BL. The risk of mortality in patients with psoriasis: results from a population-based study. Archives of dermatology. 2007 Dec 1;143(12):1493-9.
  13. Salahadeen E, Torp‐Pedersen C, Gislason G, Hansen PR, Ahlehoff O. Nationwide population‐based study of cause‐specific death rates in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology. 2015 May;29(5):1002-5.
  14. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney international. 2000 Jul 1;58(1):353-62.
  15. Stocker R, Keaney Jr JF. Role of oxidative modifications in atherosclerosis. Physiolo-gical reviews. 2004 Oct;84(4):1381-478.
  16. Vasudevan D.M. (2010) Textbook of medical Biochemistry for medical students. Jaypee publisher
  17. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. New England Journal of Medicine. 2007 Sep 27;357(13):1301-10.
  18. Hall JE, Crook ED, Jones DW, Wofford MR, Dubbert PM. Mechanisms of obesity-associated cardiovascular and renal disease. The American journal of the medical sciences. 2002 Sep 1;324(3):127-37.
  19. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983 May;67(5):968-77.
  20. Mallbris L, Akre O, Granath F, Yin L, Lindelöf B, Ekbom A, Ståhle-Bäckdahl M. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. European journal of epidemiology. 2004 Mar 1;19(3):225-30.
  21. Akhyani M, Ehsani AH, Robati RM, Robati AM. The lipid profile in psoriasis: a controlled study. Journal of the European Academy of Dermatology and Venereology. 2007 Nov;21(10):1330-2.
  22. Piskin S, Gurkok F, Ekuklu G, Senol M. Serum lipid levels in psoriasis. Yonsei medical journal. 2003 Feb 1;44(1):24-6.
  23. Reynoso-von Drateln C, Martínez-Abundis E, Balcázar-Muñoz BR, Bustos-Saldaña R, González-Ortiz M. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. Journal of the American Academy of Dermatology. 2003 Jun 1;48(6):882-5.
  24. Gertler MM, Garn SM, Bland EF. Age, serum cholesterol and coronary artery disease. Circulation. 1950 Oct;2(4):517-22.
  25. Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's disease: the cholesterol connection. Nature neuroscience. 2003 Apr;6(4):345.
  26. Miettinen TA. Mechanism of serum cholesterol reduction by thyroid hormones in hypothyroidism. The Journal of laboratory and clinical medicine. 1968 Apr 1;71(4):537-47.
  27. Keaney Jr JF, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, Benjamin EJ. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arteriosclerosis, thrombosis, and vascular biology. 2003 Mar 1;23(3):434-9.
  28. Takeda A, Higuchi D, Takahashi T, Ogo M, Baciu P, Goetinck PF, Hibino T. Overexpression of serpin squamous cell carcinoma antigens in psoriatic skin. Journal of investigative dermatology. 2002 Jan 1;118(1):147-54.
  29. Lea Jr WA, Cornish HH, Block WD. Studies on serum lipids, proteins, and lipoproteins in psoriasis. Journal of Investigative Dermatology. 1958 Apr 1;30(4):181-5.
  30. MADDEN JF. Cholesterol balance and low fat diet in psoriasis. Archives of Dermatology and Syphilology. 1939 Feb 1;39(2):268-77.
  31. Toker A, Kadı M, Yıldırım AK, Aksoy H, Akçay F. Serum lipid profile paraoxonase and arylesterase activities in psoriasis. Cell Biochemistry and Function: Cellular biochemistry and its modulation by active agents or disease. 2009 Apr;27(3):176-80.
  32. Pietrzak A, Lecewicz-Toruń B. Activity of serum lipase [EC 3.1. 1.3] and the diversity of serum lipid profile in psoriasis. Medical Science Monitor. 2002 Jan 9;8(1):CR0-
  33. Res PC, Piskin G, de Boer OJ, van der Loos CM, Teeling P, Bos JD, Teunissen MB. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PloS one. 2010 Nov 24;5(11):e14108.
  34. Andreakos E, Foxwell B, Feldmann M. Is targeting Toll‐like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine‐driven inflammation?. Immunological reviews. 2004 Dec;202(1):250-65.
  35. Honda H, Hirano T, Ueda M, Kojima S, Mashiba S, Hayase Y, Michihata T, Shibata T. High-density lipoprotein subfractions and their oxidized subfraction particles in patients with chronic kidney disease. Journal of atherosclerosis and thrombosis. 2015:30015.
  36. Kubota M, Nakanishi S, Hirano M, Maeda S, Yoneda M, Awaya T, Yamane K, Kohno N. Relationship between serum cholesterol efflux capacity and glucose intolerance in Japanese-Americans. Journal of atherosclerosis and thrombosis. 2014 Oct 24;21(10):1087-97.
  37. Villard EF, EI Khoury P, Frisdal E, Bruckert E, Clement K, Bonnefont-Rousselot D, Bittar R, Le Goff W, Guerin M. Genetic determination of plasma cholesterol efflux capacity is gender-specific and independent of HDL-cholesterol levels. Arteriosclerosis, thrombosis, and vascular biology. 2013 Apr;33(4):822-8.
  38. Einarsson K, Nilsell K, Leijd B, Angelin B. Influence of age on secretion of cholesterol and synthesis of bile acids by the liver. New England Journal of Medicine. 1985 Aug 1;313(5):277-82.

Corresponding Author

Dr Amitabh Agarwal

Associate Professor, Department of Physiology, T. S. M. Medical College & Hospital, Lucknow,

Uttar Pradesh, India